333PD - Meta-analysis Of The Effect Of Rituximab İn The Treatment Of Primary Central Nervous System Lymphoma

Date 09 September 2017
Event ESMO 2017 Congress
Session CNS tumours
Topics Anti-Cancer Agents & Biologic Therapy
Central Nervous System Malignancies
Presenter Sinan Yavuz
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors S. Yavuz1, M. Yildirim2, G. Yazıcı3, V. Kaya4, S. Paydas5
  • 1Medical Oncology, Acıbadem University, 01735 - Adana/TR
  • 2İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR
  • 3Department Of Radiation Oncology, Hacettepe University School of Medicine, Ankara/TR
  • 4Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 5Medical Oncology, Cukurova University, 01330 - Adana/TR

Abstract

Background

Primary central nervous system lymphoma (PCNSL) is a rare subtype of agressive non-hodgkin lymphoma (NHL), and is most commonly of B cell phenotype. The standard treatment is not well established but high dose methotraxate is the most commonly used regimen. Intravenous rituximab (iv Rtx) treatment is integrated into the protocols for systemic B cell lymphomas. However there are mixed results with the use of Rtx. The aim of this meta-analysis is to investigate the role of iv Rtx in the treatment of PCNSL.

Methods

PubMed and EBSCOhost databases are searched for rituximab, primary central nervous lymphoma, rituximab, survival. Browsing databases was done in English.

Results

580 patients were included to meta-analysis. Pooled hazard ratio showed that overall survival is correlated with iv Rtx (HR, 0,498; 95% CI, 0,366 - 0,678; p:

Conclusions

In this meta-analysis, we showed that the addition of iv Rtx as part of a treatment protocol for PCNSL has a positive impact on survival.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım

Funding

None

Disclosure

All authors have declared no conflicts of interest.